Microbot Medical (MBOT)
(Delayed Data from NSDQ)
$0.93 USD
-0.01 (-1.25%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $0.94 +0.01 (1.58%) 7:04 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MBOT 0.93 -0.01(-1.25%)
Will MBOT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MBOT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MBOT
Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY
Microbot Medical (MBOT) Gets Quality Certification for its System
MBOT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Microbot Medical (MBOT) Inks Deal to Test Autonomous Robotics
Microbot Medical (MBOT) Progresses in Its Human Clinical Trial
Microbot Medical (MBOT) Inks Agreement to Begin LIBERTY Trial
Other News for MBOT
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System
Microbot Medical Advances in Endovascular Robotic Trials
Microbot Medical announces enrollment of 50% of patients in ACCESS-PVI trial
Microbot Medical signs Phase 2 agreement with Corewell Health
Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY? Endovascular Robotic System